Sign In
Buy PLRX
$1.18
+0.0200 (+1.72%)
At Close: Jun 03, 2026
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
01:53pm, Thursday, 04'th Dec 2025
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
07:30am, Thursday, 04'th Dec 2025
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatme
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
08:30am, Monday, 01'st Dec 2025
SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based thera
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
04:05pm, Thursday, 06'th Nov 2025
Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NE
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
04:05pm, Thursday, 07'th Aug 2025
BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year S
Pliant Therapeutics Provides Update on BEACON-IPF
04:05pm, Friday, 27'th Jun 2025
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
04:03pm, Wednesday, 21'st May 2025
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical da
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
04:05pm, Thursday, 08'th May 2025
Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
04:05pm, Thursday, 01'st May 2025
- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
12:01pm, Friday, 25'th Apr 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investor
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
10:30am, Wednesday, 23'rd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
05:26pm, Monday, 21'st Apr 2025
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investor
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
04:21pm, Monday, 21'st Apr 2025
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such inves
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
09:30am, Sunday, 20'th Apr 2025
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investor
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
01:45pm, Friday, 18'th Apr 2025
NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investor
